柬埔寨间日疟:高剂量与低剂量伯氨喹14天疗效对比
在柬埔寨开展的一项随机、单中心、开放标签试验中,147例间日疟患者完成分析,90天内无伯氨喹组复发率81%,低剂量组24%,高剂量组5%(高剂量与低剂量比较P=0.0141)。高剂量伯氨喹(7.0 mg/kg)较低剂量(3.5 mg/kg)显著降低复发风险,两种方案耐受性均良好,未报告严重不良事件。
要点
- 高剂量伯氨喹(7.0 mg/kg)组90天内复发率5%,低剂量组24%,无伯氨喹组81%。
- 高剂量较低剂量显著降低复发风险(HR 0.17,95%CI 0.04-0.79,P=0.0229)。
- G6PD正常者中两种伯氨喹方案耐受性和安全性相当,未报告严重不良事件。
核心结论
- 不给予伯氨喹的患者间日疟复发率相当高。
- 7.0 mg/kg伯氨喹治疗较3.5 mg/kg显著降低间日疟复发风险。
- G6PD正常个体中两种伯氨喹方案的耐受性和安全性相当。
研究设计与样本
- 开放标签、随机对照试验,在柬埔寨磅士卑省开展,随访期间患者迁至高棉省奥拉尔镇无疟疾传播地区居住。
- 纳入160例间日疟患者,147例纳入主要分析;G6PD正常者按2:2:1随机分配至低剂量伯氨喹、高剂量伯氨喹或无伯氨喹组,G6PD缺乏者分配至无伯氨喹对照组。
- 所有患者先接受青蒿琥酯2 mg/kg每日一次、共7天治疗;伯氨喹疗程14天。
- 主要结局为迁居随访90天内间日疟复发,在完成治疗且不间断遵守迁居的患者中评估。
- 试验注册号NCT04706130,招募已完成。
主要发现
- 2021年11月10日至2024年2月10日招募160例患者,147例纳入主要分析:无伯氨喹组59例(其中37例为G6PD缺乏者,中位年龄22岁,IQR 18-28;22例随机分配,中位年龄18岁,IQR 17-25),低剂量伯氨喹组45例(中位年龄23岁,IQR 19-30),高剂量伯氨喹组43例(中位年龄22岁,IQR 18-25)。
- 参与者多为男性(135/147,92%),均为柬埔寨人。
- 90天内至少一次间日疟复发:无伯氨喹组48例(81%,95%CI 69.6-89.2),低剂量组11例(24%,95%CI 14.2-38.7),高剂量组2例(5%,95%CI 0.8-15.5);高剂量与低剂量比较P=0.0141。
- 缺失数据填补后,低剂量伯氨喹复发风险仍高于高剂量伯氨喹(HR 0.17,95%CI 0.04-0.79,P=0.0229)。
- 两种伯氨喹方案耐受性均良好,未报告严重不良事件。
关键数值与推荐
- 无伯氨喹组90天内复发率81%(95%CI 69.6-89.2)。
- 低剂量伯氨喹组(3.5 mg/kg,即0.25 mg/kg/日,14天)90天内复发率24%(95%CI 14.2-38.7)。
- 高剂量伯氨喹组(7.0 mg/kg,即0.5 mg/kg/日,14天)90天内复发率5%(95%CI 0.8-15.5)。
- 高剂量与低剂量比较P=0.0141;缺失数据填补后HR 0.17(95%CI 0.04-0.79),P=0.0229。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most malaria-endemic countries, including Cambodia, use a total dose of 3·5 mg/kg of primaquine to eliminate Plasmodium vivax hypnozoites and prevent relapses. There are, however, indications that the lower dose of 3·5 mg/kg is insufficient for tropical P vivax isolates, particularly in southeast Asia, and WHO now recommends a total dose of 7·0 mg/kg in most countries. We aimed to determine the most effective regimen to eliminate P vivax hypnozoites to support elimination efforts of this malaria parasite. METHODS: We conducted an open-label, randomised controlled trial in Kampong Speu province, western Cambodia. Patients infected with P vivax aged at least 15 years were offered to participate. Exclusion criteria were severe malaria or other diseases requiring treatment, low haemoglobin (<8·0 g/dL), pregnancy or breastfeeding, sensitivity to study drugs, and use of antimalarials in the preceding month. Enrolled patients were treated with an artesunate regimen of 2 mg/kg per day for 7 days. Patients with normal glucose-6-phosphate dehydrogenase (G6PD) levels were randomly assigned (2:2:1) to receive 3·5 mg/kg (low dose [0·25 mg/kg per day]), 7·0 mg/kg (high dose [0·5 mg/kg per day]), or no primaquine for 14 days. Patients with deficient G6PD levels were assigned to the no primaquine comparator arm. Patients were relocated to the study site in Aoral town where no malaria transmission occurs to ensure that they were not reinfected during their 90-day follow-up. After 90 days of relocation, G6PD-normal patients in the no primaquine arm were provided 3·5 mg/kg of primaquine for 14 days to be taken unsupervised. At day 90, relocation was terminated, and patients were followed up monthly for 3 months until day 180. The primary outcome was P vivax recurrence within 90 days of relocated follow-up, assessed in all patients who completed treatment and complied with relocation without interruption. All patients enrolled and assigned to an intervention arm were included in the safety analysis. The study is registered on ClinicalTrials.gov and recruitment is completed (NCT04706130). FINDINGS: Between Nov 10, 2021, and Feb 10, 2024, 160 patients were enrolled and 147 were included in the primary analysis-59 were assigned to the no primaquine arm (37 assigned as G6PD deficient [median age 22 years, IQR 18-28]; 22 randomly assigned [18, 17-25]), 45 to the low-dose primaquine arm (23, 19-30), and 43 to the high-dose primaquine arm (22, 18-25). Participants were mostly male (135 [92%] of 147) and all Cambodian. 48 (81% [95% CI 69·6-89·2]) participants in the no primaquine arm had at least one P vivax recurrence within 90 days, as did 11 (24%, 14·2-38·7) in the low-dose group and two (5%, 0·8-15·5) in the high-dose group (p=0·0141 for high vs low). After imputation for missing data, low-dose primaquine remained associated with more recurrences than high-dose primaquine (hazard ratio 0·17 [95% CI 0·04-0·79], p=0·0229). Both primaquine regimens were well tolerated with no serious adverse events reported. INTERPRETATION: Not providing primaquine to patients led to a considerable rate of P vivax recurrence. The risk of P vivax recurrence was substantially lower for 7·0 mg/kg primaquine treatment compared with 3·5 mg/kg. Tolerability and safety of both primaquine regimens in G6PD normal individuals was comparable. FUNDING: US National Institutes of Health (R01AI146590).
引用
- Eng V, Lek D, Sin S, et al. 14 days of high-dose versus low-dose primaquine treatment in patients with Plasmodium vivax infection in Cambodia: a randomised, single-centre, open-label efficacy study. Lancet Infect Dis. 2025. PMID: 40112852. doi:10.1016/S1473-3099(25)00033-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。